Integra LifeSciences to Present at Significant Healthcare Conference
Integra LifeSciences Holdings Corporation (NASDAQ: IART), a prominent name in the global medical technology arena, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. Scheduled for March 17, 2025, at 10:00 AM ET, this presentation is anticipated to highlight the company's innovative approaches and contributions to the medical field.
Company Leadership to Take Center Stage
The conference will feature Mojdeh Poul, the chief executive officer, alongside Lea Knight, the chief financial officer of Integra. Their presentation aims to provide insights into the company's strategic direction and how it continues to impact patient outcomes positively. Stakeholders and interested parties can expect a detailed overview of Integra's latest advancements and future plans.
Live Webcast Available for Investors
For those unable to attend in person, a live webcast of the presentation will be accessible via the Integra LifeSciences investor relations website. This initiative reflects the company's commitment to transparency and engagement with its investors. By providing an online streaming option, Integra ensures that a wider audience can participate in this vital event.
About Integra LifeSciences: Mission and Vision
At the heart of Integra LifeSciences is the mission to restore patients' lives through innovative medical solutions. The company is dedicated to advancing treatment pathways and improving surgical outcomes, neurologic care, and regenerative treatment practices. With a diverse portfolio of high-quality brands, Integra leads the way in setting new standards within the healthcare industry.
Contact Information for Investor Relations
Integra encourages inquiries and invites discussions through its dedicated investor relations contact, Chris Ward. For any questions regarding the upcoming conference or company performance, investors can reach out via phone at (609) 772-7736 or through email for personalized assistance. The investor relations team is always ready to provide support and information as needed.
Media Inquiries Made Easy
For media-related inquiries, the designated contact is Laurene Isip. She can be reached at (609) 208-8121, ensuring that all press-related questions and communications are efficiently handled. Integra places a high priority on clear communication and remains open to media collaboration.
Integra's Commitment to Innovation
As a leader in medical technology, Integra LifeSciences is continuously focused on research and development. This commitment reflects in how the company innovates treatment options that significantly advance patient care. By investing in cutting-edge technologies and fostering a culture of innovation, Integra remains at the forefront of medical advancements.
Frequently Asked Questions
What is the main focus of Integra LifeSciences at the conference?
Integra will focus on its strategic innovations in medical technology and how it enhances patient outcomes.
Who will represent Integra at the Oppenheimer conference?
CEO Mojdeh Poul and CFO Lea Knight will represent Integra LifeSciences at the event.
Will there be a way to watch the presentation if I cannot attend?
Yes, the presentation will be available via a live webcast on the Integra investor relations website.
How does Integra LifeSciences contribute to patient care?
Integra innovates treatment pathways and offers a comprehensive portfolio to improve surgical and regenerative care.
Who can I contact for investor inquiries about Integra?
Chris Ward is the contact for investor relations, and he can be reached at (609) 772-7736.
